Economics of Health Technology Assessment

Cubi-Molla, P., Mott, D., Shah, K., Herdman, M., Summers, Y. and Devlin, N.

Consulting Report
June 2018

Cancer survival rates have improved dramatically in recent decades due in part to pharmaceutical advances, with a growing range of increasingly effective and targeted medicines being developed, such as immunotherapies. In the economic modelling of such treatments, the question arises of which utilities should be assigned to patients who show a long-term, durable response.

In recent critiques of economic models in this area by the National Institute for Health and Care Excellence (NICE), the idea that long-term cancer survivors (LTCS) who have received such treatments could report quality of life (QoL) scores which are similar to, or higher than, those of equivalent general population samples has not been viewed as credible. This literature review examines whether there is evidence to support the assumption that the QoL of LTCS can be similar to that of age/sex-matched population samples.

This study was funded by Roche Products Ltd.

Meet some of the OHE team at the Health Technology Assessment International (HTAi) 2018 conference in Vancouver, 1-5 June.

OHE’s Professor Nancy Devlin has been elected as ISPOR’s incoming President.

Meet some of the OHE team at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2018 conference in Baltimore, 19-23 May.

OHE, in collaboration with RAND Europe and King’s College, has been awarded a research grant from Cancer Research UK exploring outcome-based payments.

OHE is on RePEc: find publications from the Office of Health Economics in Research Papers in Economics.

OHE’s Prof Nancy Devlin has been collaborating on a new approach to creating personal and social EQ-5D-5L value sets, based on a web application.

Just published are two new reports that explore the use of real world evidence for coverage and formulary decisions. The publications represent 1) the background paper to the 2017 ICER Membership Policy Summit and 2) a follow up paper based on the discussion at the Summit.

Neri, M. and Towse, A.

Briefing
October 2017

This briefing provides a detailed summary of a symposium held at the HTAi 2017 meeting in Rome.

Karlsberg Schaffer, S., West, P., Towse, A., Henshall, C., Mestre-Ferrandiz, J., Masterson, R., and Fischer, A.

Briefing
May 2017

Antimicrobial resistance (AMR) occurs when microorganisms such as bacteria, viruses, fungi and parasites change in ways that render the medications used to cure the infections they cause ineffective.

Pages

Subscribe to RSS - Economics of Health Technology Assessment